Recursion Announces $200 Million Follow-On Offering, Clinical Data Updates and Partnership Milestone
Recursion announced a $200 million oversubscribed follow-on offering, clinical data updates and a partnership milestone.
Story updates
12:28:15 PM UTC
SquawkNews
Recursion announced an underwritten $200M common stock offering, updated Phase 1b/2 REC-4881 and Phase 1 REC-1245 data, and a $10M milestone as Sanofi optioned an immunology candidate from their collaboration.Material DetailsContext by AI AnalystThis fits Recursion’s push to convert its AI platform…
12:30:10 PM UTC
SquawkNews
RXRX - Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
12:38:12 PM UTC
SquawkNews
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock